Sebastian Szmit: Advances in Managing Cancer-Associated Thromboembolism
OncoDaily shared on LinkedIn:
”Dr. Sebastian Szmit Highlights Advances in Managing Cancer-Associated Thromboembolism at GCOS 2025
Dr. Sebastian Szmit, from the Institute of Hematology and Transfusion Medicine and the Center of Postgraduate Medical Education in Warsaw, delivered an engaging talk on cancer-associated thromboembolism. He discussed premature mortality linked to VTE in cancer patients and reviewed ESC guideline–based anticoagulation options, comparing DOACs (apixaban, edoxaban, rivaroxaban) with low-molecular-weight heparin (LMWH). He emphasized that while DOACs are effective, LMWH remains preferred in gastrointestinal cancers due to higher bleeding risks.
Dr. Szmit also presented findings from the APICAT study, which showed that a reduced dose of apixaban can maintain efficacy while lowering bleeding risk during extended anticoagulation. He highlighted challenges such as drug interactions, thrombocytopenia, and the need for improved primary prophylaxis strategies tailored to cancer therapy.”
Stay informed with Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia